ID   SU-DHL-1
AC   CVCL_0538
SY   SU-DHL1; SUDHL1; SUDHL-1; SuDHL-1; SuDHL 1; Stanford University-Diffuse Histiocytic Lymphoma-1
DR   BTO; BTO:0005058
DR   CLO; CLO_0009160
DR   EFO; EFO_0005461
DR   MCCL; MCC:0000439
DR   AddexBio; C0003020/4894
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CRL-2955
DR   BioSample; SAMN03471710
DR   BioSample; SAMN10988544
DR   CCLE; SUDHL1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   Cell_Model_Passport; SIDM00390
DR   ChEMBL-Cells; CHEMBL3308303
DR   ChEMBL-Targets; CHEMBL2366200
DR   Cosmic; 909742
DR   Cosmic; 946364
DR   Cosmic; 1086003
DR   Cosmic; 1086367
DR   Cosmic; 1086753
DR   Cosmic; 1152235
DR   Cosmic; 1995646
DR   Cosmic; 2361379
DR   Cosmic; 2674496
DR   Cosmic-CLP; 909742
DR   DepMap; ACH-000664
DR   DSMZ; ACC-356
DR   GDSC; 909742
DR   GEO; GSM887652
DR   GEO; GSM888744
DR   GEO; GSM1217155
DR   GEO; GSM1670482
DR   IARC_TP53; 27247
DR   LiGeA; CCLE_319
DR   LINCS_LDP; LCL-1918
DR   PharmacoDB; SUDHL1_1499_2019
DR   Progenetix; CVCL_0538
DR   Wikidata; Q54970705
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   DOI=10.1159/000415060;
RX   PubMed=83902;
RX   PubMed=214220;
RX   PubMed=371794;
RX   PubMed=2525056;
RX   PubMed=3881165;
RX   PubMed=4140017;
RX   PubMed=8547074;
RX   PubMed=8558920;
RX   PubMed=9121481;
RX   PubMed=9738977;
RX   PubMed=11021758;
RX   PubMed=11494142;
RX   PubMed=15356658;
RX   PubMed=16596703;
RX   PubMed=17170727;
RX   PubMed=20164919;
RX   PubMed=20922763;
RX   PubMed=22460905;
RX   PubMed=25355872;
RX   PubMed=25485619;
RX   PubMed=26657151;
RX   PubMed=27397505;
RX   PubMed=29899875;
RX   PubMed=30285677;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: ~40-50 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; NPM1-ALK (PubMed=9121481; PubMed=25485619; PubMed=26657151; PubMed=29899875).
CC   Sequence variation: Heterozygous for TP53 p.Arg273His (c.818G>A) (ClinVar=VCV000012366) (Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Omics: Virome analysis using RNAseq.
CC   Genome ancestry: African=3.76%; Native American=22.55%; East Asian, North=5.57%; East Asian, South=0%; South Asian=0%; European, North=43.3%; European, South=24.81% (PubMed=30894373).
CC   Derived from sampling site: Pleural effusion.
ST   Source(s): AddexBio; ATCC; COG; Cosmic-CLP; DSMZ; PubMed=20922763; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 9,13
ST   D16S539: 11,12
ST   D18S51: 15
ST   D19S433: 12,16
ST   D21S11: 29,30
ST   D2S1338: 19,20
ST   D3S1358: 15 (COG; PubMed=25877200)
ST   D3S1358: 15,16 (PubMed=20922763)
ST   D5S818: 11,12
ST   D7S820: 10,13
ST   D8S1179: 11
ST   FGA: 21
ST   Penta D: 14
ST   Penta E: 11,15
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 15,17
DI   NCIt; C37193; Anaplastic large cell lymphoma, ALK-positive
DI   ORDO; Orphanet_300895; ALK-positive anaplastic large cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   10Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-01-21; Version: 35
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   DOI=10.1159/000415060;
RA   Morikawa S., Harada T., Katoh T.;
RT   "Heterogeneity of cellular origins in human malignant lymphoma cell
RT   line derived from histo-monocytic lineage cells.";
RL   (In) Cellular, molecular, genetic approaches to immunodiagnosis and immunotherapy. 8th International conference on labeled antibodies, Tokyo, November 1985; Kano K., Mori S., Sugisaki T., Torisu M. (eds.); pp.373-380; Karger; Basel (1988).
//
RX   PubMed=83902; DOI=10.1002/1097-0142(197901)43:1<1::AID-CNCR2820430102>3.0.CO;2-M;
RA   Kaplan H.S., Goodenow R.S., Gartner S., Bieber M.M.;
RT   "Biology and virology of the human malignant lymphomas: 1st Milford D.
RT   Schulz Lecture.";
RL   Cancer 43:1-24(1979).
//
RX   PubMed=214220; DOI=10.1002/1097-0142(197811)42:5<2379::AID-CNCR2820420539>3.0.CO;2-4;
RA   Epstein A.L., Levy R., Kim H., Henle W., Henle G., Kaplan H.S.;
RT   "Biology of the human malignant lymphomas. IV. Functional
RT   characterization of ten diffuse histiocytic lymphoma cell lines.";
RL   Cancer 42:2379-2391(1978).
//
RX   PubMed=371794;
RA   Epstein A.L., Kaplan H.S.;
RT   "Feeder layer and nutritional requirements for the establishment and
RT   cloning of human malignant lymphoma cell lines.";
RL   Cancer Res. 39:1748-1759(1979).
//
RX   PubMed=2525056; DOI=10.1182/blood.V73.8.2155.2155;
RA   Morgan R., Smith S.D., Hecht B.K., Christy V., Mellentin J.D.,
RA   Warnke R., Cleary M.L.;
RT   "Lack of involvement of the c-fms and N-myc genes by chromosomal
RT   translocation t(2;5)(p23;q35) common to malignancies with features of
RT   so-called malignant histiocytosis.";
RL   Blood 73:2155-2164(1989).
//
RX   PubMed=3881165; DOI=10.1016/0165-4608(85)90186-4;
RA   Hecht B.K., Epstein A.L., Berger C.S., Kaplan H.S., Hecht F.;
RT   "Histiocytic lymphoma cell lines: immunologic and cytogenetic
RT   studies.";
RL   Cancer Genet. Cytogenet. 14:205-218(1985).
//
RX   PubMed=4140017; DOI=10.1002/1097-0142(197412)34:6<1851::AID-CNCR2820340602>3.0.CO;2-4;
RA   Epstein A.L., Kaplan H.S.;
RT   "Biology of the human malignant lymphomas. I. Establishment in
RT   continuous cell culture and heterotransplantation of diffuse
RT   histiocytic lymphomas.";
RL   Cancer 34:1851-1872(1974).
//
RX   PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x;
RA   Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G.,
RA   Uppenkamp M., Nowrousian M.R., Seeber S., Opalka B.;
RT   "Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and
RT   lymphoblastic leukaemia cell lines.";
RL   Br. J. Haematol. 91:350-354(1995).
//
RX   PubMed=8558920;
RA   Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M.,
RA   Quentmeier H., Drexler H.G.;
RT   "The (2;5)(p23;q35) translocation in cell lines derived from malignant
RT   lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.";
RL   Leukemia 10:142-149(1996).
//
RX   PubMed=9121481; DOI=10.1128/mcb.17.4.2312;
RA   Bischof D., Pulford K., Mason D.Y., Morris S.W.;
RT   "Role of the nucleophosmin (NPM) portion of the non-Hodgkin's
RT   lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in
RT   oncogenesis.";
RL   Mol. Cell. Biol. 17:2312-2325(1997).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=11021758; DOI=10.1038/sj.leu.2401891;
RA   Majka M., Rozmyslowicz T., Honczarenko M., Ratajczak J., Wasik M.A.,
RA   Gaulton G.N., Ratajczak M.Z.;
RT   "Biological significance of the expression of HIV-related chemokine
RT   coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic
RT   cell lines.";
RL   Leukemia 14:1821-1832(2000).
//
RX   PubMed=11494142; DOI=10.1038/sj.onc.1204582;
RA   Turturro F., Frist A.Y., Arnold M.D., Seth P., Pulford K.;
RT   "Biochemical differences between SUDHL-1 and KARPAS 299 cells derived
RT   from t(2;5)-positive anaplastic large cell lymphoma are responsible
RT   for the different sensitivity to the antiproliferative effect of
RT   p27(Kip1).";
RL   Oncogene 20:4466-4475(2001).
//
RX   PubMed=15356658; DOI=10.1038/sj.leu.2403465;
RA   Drexler H.G., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   anaplastic large-cell lymphoma.";
RL   Leukemia 18:1569-1571(2004).
//
RX   PubMed=16596703; DOI=10.1002/pmic.200500647;
RA   Cussac D., Pichereaux C., Colomba A., Capilla F., Pont F.,
RA   Gaits-Iacovoni F., Lamant L., Espinos E., Burlet-Schiltz O.,
RA   Monsarrat B., Delsol G., Payrastre B.;
RT   "Proteomic analysis of anaplastic lymphoma cell lines: identification
RT   of potential tumour markers.";
RL   Proteomics 6:3210-3222(2006).
//
RX   PubMed=17170727; DOI=10.1038/sj.leu.2404486;
RA   Sandberg Y., Verhaaf B., van Gastel-Mol E.J., Wolvers-Tettero I.L.M.,
RA   de Vos J., MacLeod R.A.F., Noordzij J.G., Dik W.A., van Dongen J.J.M.,
RA   Langerak A.W.;
RT   "Human T-cell lines with well-defined T-cell receptor gene
RT   rearrangements as controls for the BIOMED-2 multiplex polymerase chain
RT   reaction tubes.";
RL   Leukemia 21:230-237(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20922763; DOI=10.1002/pbc.22801;
RA   Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J.,
RA   Reynolds C.P.;
RT   "National Cancer Institute pediatric preclinical testing program:
RT   model description for in vitro cytotoxicity testing.";
RL   Pediatr. Blood Cancer 56:239-249(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14;
RA   Cao S., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=26657151; DOI=10.1038/onc.2015.456;
RA   Ceccon M., Merlo M.E.B., Mologni L., Poggio T., Varesio L.M.,
RA   Menotti M., Bombelli S., Rigolio R., Manazza A.D., Di Giacomo F.,
RA   Ambrogio C., Giudici G., Casati C., Mastini C., Compagno M.,
RA   Turner S.D., Gambacorti-Passerini C., Chiarle R., Voena C.;
RT   "Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and
RT   drug dependency.";
RL   Oncogene 35:3854-3865(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29899875; DOI=10.18632/oncotarget.25489;
RA   Krumbholz M., Woessmann W., Zierk J., Seniuk D., Ceppi P.,
RA   Zimmermann M., Singh V.K., Metzler M., Damm-Welk C.;
RT   "Characterization and diagnostic application of genomic NPM-ALK fusion
RT   sequences in anaplastic large-cell lymphoma.";
RL   Oncotarget 9:26543-26555(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940-940(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//